Johnson & Johnson: Business Perimeter, Product Mix and Cash

Johnson & Johnson reported FY2025 sales of $94.193 billion, split between Innovative Medicine and MedTech. Operating cash of $24.530 billion less $4.832 billion of property additions left a derived $19.698 billion. Acquisition, research and litigation cash still require separate treatment; the reported reserve reversal was not a cash receipt.

Latest released reporting at October 25, 2026

Q3 2026 covers 2026-06-29 through 2026-09-27 and was released 2026-10-13. Revenue was $25,399 million in this quarter. Source: official Q3 2026 results.

The later quarter's profit includes a proposed talc-resolution charge and acquired research. Revenue growth does not establish settlement cash paid or eliminate legal risk; the separated Consumer Health business remains outside the current operating case.

Full-year revenue (reported)

Reported whole-company revenue, before operating expenses and reinvestment; it is not a cash-flow or valuation measure. Source: FY2025 annual report and comparative statements.

Medicines and medical technology define the relevant business

Johnson & Johnson's cited reporting covers medicines in Innovative Medicine and medical technology in MedTech. These are different product businesses serving healthcare needs; the separated Consumer Health operation is outside the continuing-business sales table.

The reported $60,401 million of medicine sales and $33,792 million of MedTech sales describe two operating populations, while the cash-flow table is consolidated. Product development, acquired research and physical assets have different funding schedules. The cash left after property additions does not allocate those costs between the businesses, and litigation accounting remains separate from the commercial cash case.

Reconcile the two reported businesses

The January 21, 2026 annual results report the sales categories below for the fiscal year ended December 28, 2025. The FY2025 Form 10-K filed February 11, 2026 supplies the consolidated cash-flow amounts. All amounts are $ millions and relate to Johnson & Johnson and its consolidated subsidiaries.

The revenue reconciliation is 60,401 + 33,792 = 94,193. The cash residual is a starting bridge after physical investment, rather than a statement of cash remaining after all acquired research, licensing, business purchases and financing obligations. Those transactions require their own cash-flow rows.

Compare the same perimeter across periods

The annual filing treats the separated Consumer Health business as discontinued operations and cautions that its 2023 cash-flow amounts were not recast to exclude those operations. This makes an unqualified comparison of old group cash with the selected continuing-business sales misleading. Use the source's reconciliation instead of assuming that a familiar company name always represents the same activities.

Acquisition dates matter within a single annual period as well. The filing places Intra-Cellular Therapies in the group from April 2, 2025 and reports the Halda acquisition late in the year. For a forward case, identify which acquired results are partial-year, which costs support the acquired activity and whether a proposed full-year contribution is an analyst assumption. Do not buy an asset in the cash bridge while assuming its revenue was already present throughout the comparison year.

Distinguish litigation accounting from payment timing

The FY2025 filing reports an approximately $7.0 billion reversal of previously accrued talc reserves. That accounting reversal is not a cash receipt. A forecast needs a separate bridge for the opening liability, new expense or reversal, actual payments and remaining obligations, with source dates attached.

There is a later development to keep visible: the October 13, 2026 results release reports a special charge relating to a proposed talc litigation resolution. The 2025 reversal therefore cannot be presented as the current final outcome or as evidence that future litigation cash is zero. This page does not calculate a settlement forecast from either announcement.

Build product cases before normalizing group cash

Within the operating case, distinguish established-product demand, competitive or exclusivity pressure, and the contribution expected from acquired or newly launched products. State any product-life or replacement assumption explicitly. Neither an acquired pipeline asset's accounting value nor a patent date by itself establishes the commercial cash it will produce.

One analyst scenario can delay an acquired product's contribution while retaining research and integration spending. Another can change an established product's sales path and test the group cash effect after taxes, inventory and reinvestment. Keep transaction cash and litigation payments visible rather than removing every unusual item to create an unexplained recurring margin.

What customers pay for and what changes the economics

Innovative Medicine sells prescription treatments through healthcare channels, while MedTech supplies products for cardiovascular procedures, orthopaedics, surgery and vision. Some medicines are licensed or developed with partners. The FY2025 filing describes royalties on DARZALEX and expected continuing STELARA biosimilar pressure. Product revenue therefore differs from the contribution retained after partner payments, and MedTech demand follows procedures and professional adoption rather than prescription volume. (FY2025 source.)

Analysis: Build medicine contribution after royalties and commercialization costs, then assess MedTech through procedure activity, product use and capital-equipment adoption. A product launch replacing an eroding medicine can preserve sales without preserving the same retained margin. Likewise, a hospital equipment placement should not be treated as proof that every associated procedure will use the expected consumables.

Operating signals to carry into the forecast

Watch these signals on a consistent period and definition. Undisclosed measures remain questions to investigate, rather than supplied KPI data.

• Medicine growth by franchise: separate new uptake from erosion in exposed products.
• Retained product contribution: include partner royalties and launch costs before assuming mix improves margin.
• MedTech procedure and product-use trends: distinguish installed equipment from recurring utilization.
• Acquired-program and legal cash: preserve separate funding schedules rather than normalize all charges away.

SWOT and the forecast consequence

SWOT classifications and forecast consequences are analytical judgments; evidence uses the dated sources cited below.

Valuation implication: The decisive test is whether replacement growth preserves retained contribution after research, royalties and investment. Compare product erosion with slower MedTech adoption, keeping their cash requirements separate. The existing litigation and acquisition bridges remain necessary before deriving shareholder value.

The manual company forecast accepts your assumptions, and the DCF calculator requires a consistent cash and discount-rate basis. The Microsoft financial analysis provides another operating-to-cash methodology. This page supplies selected historical reporting, not a current pro-forma group or live share valuation.